Lupin’s EMEA President Thierry Volle explains that to fuel growth in the EMEA region, Lupin is investing heavily in transforming the business from a generics company into a specialty pharma player.
Mr Volle, given your background in the innovative pharma sector, what was it that attracted you to join Lupin?
"Transforming a generics company into a specialty care player is an engaging challenge in terms of change management, developing a new mindset and mentality, bringing in new competencies, and carrying out the necessary structural or administrative changes."
